Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed

Executive Summary

Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.

Advertisement

Related Content

Accelerating Antibiotics: Kevin Outterson And Joe Larsen Explain CARB-X
CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands
CMS Denial of Astellas’ Cresemba Add-On Payment Could Boost Legislative Solution
Actavis Counting On Strong Product Line Depth For Avycaz Launch
Actavis builds antibiotic presence with $675m+ Durata deal
With more cha-ching, will PDUFA V satisfy on the ba-bling?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel